Skip to main content

Table 1 Comparison of anti-PD-1 adjuvant trials

From: Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

Data comparison in adjuvant melanoma trials

Patient population

CM238 [60]

COMBI-AD [61]

KN054 [4]

Completely resected stage IIIB/C or IV melanoma

Completely resected, BRAFV600E/K-positive stage IIIA/B/C melanoma

Completely resected stage IIIA/B/C melanoma

Treatment

Nivo

Lpi

Dab/Tram

Placebo

Pembro

Placebo

N

453

453

438

432

514

505

RFS HR

0.65 (97.56% CI 0.51–0.83), P < 0.0001

0.47 (95% CI 0.39–0.58), P < 0.001

0.57 (98.4% CI 0.43–0.74), P < 0.001

1-year RFS rate (%)

71

61

88

56

75

61

18-months RFS rate (%)

66

53

N/A

N/A

71

53

3-years OS rate (%)

N/A

N/A

86

77

N/A

N/A

Grade 3–5 TRAEs (%)

14

46

31

5

15

3

DC rate due to AEs (%)

10

43

26

3

14

2

  1. In italic values for 1-y RFS Rate (%), patients treated with nivolumab Grade 3-5 TREs (%) and patients treated with nivolumab DC Rate due to AEs (%)
  2. Comparison of three trials showing a consistent beneficial effect on RFS with adjuvant PD-1 inhibitor therapy, although OS data is largely still awaited